Follow the chain left → right, from inputs to end demand. Tap any company to trace its links.
Raw inputs
Equipment
Foundry
Chip design
Software
AI demand
—
Company details
Market cap
~$27B
P/E ratio
~13×
Div yield
0%
EPS (TTM)
~$8.80
Profit margin
~13%
Rev. growth
-7%
Revenue
~$9.9B
Net income
~$1.3B
In plain English
Biogen is a neuroscience-rooted biotech: it grows biologic medicines in bioreactors for multiple sclerosis (its declining cash cow) and rare disease (Spinraza for SMA, Skyclarys for Friedreich's ataxia), and co-commercialises the Alzheimer's drug Leqembi with Japan's Eisai. With its old MS franchise eroding under patent loss, it is reinventing itself through dealmaking — buying HI-Bio in immunology and completing a ~$5.6B takeover of Apellis (Syfovre, Empaveli) in May 2026.
In simple terms
What Biogen really sells
Biogen is a neuroscience-rooted biotech: it grows biologic medicines in bioreactors for multiple sclerosis (its declining cash cow) and rare disease (Spinraza for SMA, Skyclarys for Friedreich's ataxia), and co-commercialises the Alzheimer's drug Leqembi with Japan's Eisai. With its old MS franchise eroding under patent loss, it is reinventing itself through dealmaking — buying HI-Bio in immunology and completing a ~$5.6B takeover of Apellis (Syfovre, Empaveli) in May 2026.
Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.